Operator: Thank you. And our next question comes from Lance Wilkes with Bernstein. Please go-ahead.
Lance Wilkes: Great. Thanks. Can you talk a little bit about the PBM migration? And in particular, I was interested in if all the savings levers turned on January 1st or if there should be a ramp of that over the course of the year with things like formulary alignment, et-cetera? And if any of that might spill into 2025? And maybe then as a broader question, just in your ongoing dialogues with states, how are they looking at GLP-1s and kind of adding coverage to that? Thanks a lot.
Sarah London: Thanks, Lance, for the question. Mostly because I don’t think I can brag enough about our pharmacy team and the phenomenal job they did in such a massive undertaking, we’ve talked before about how well that went January 1, but I think everybody who’s been through something that significant knows that you don’t just drop the mic the next day. And so, these folks have continued to work tirelessly over the last couple of months to make sure that, that process just gets smoother and smoother for our members. We’ve had great collaboration with ESI. And so, trajectory on that front just continues to be really positive. And then, I’ll let Drew talk a little bit about the step-up in the economics and some of the GLP-1 activity.
Andrew Asher: Yes. So, we didn’t want to wait for economics. So, we do have a stair-step benefit on behalf of our state and federal customers and our members as of 1/1/24. But we’re constantly working with our partner at ESI to figure out ways to deliver value to our customers and manage costs. So, we expect sort of normal course improvements from that point forward, and we’ll continue to try to drive efficiencies in the pharmacy ecosystem. On GLP-1s, not a lot of uptake yet by states. There’s a couple of states where have decided to allow GLP-1s for the weight-loss indication. Obviously, GLP-1s for the diabetes indication, we can see the volume coming through there. But for the weight-loss indication, there’s only a couple and we’re quick to go share the data with them to show them what it’s costing them.
But it’s not that material to the Company as a whole. And that’s where the states control the formulary, the preferred drug list and make the decisions that we then administer and take risk for. And we just need to make sure that the states have the data, so they can match rates with the cost that they choose to allow in their benefit plans.
Operator: Thank you. This concludes our question-and-answer session. I’d like to turn the conference back over to Sarah London for any closing remarks.
Sarah London: Thanks, Rocco, and thanks, everyone. Appreciate the time and interest this morning. Overall, we are pleased with how we’re powering through a dynamic landscape and with the progress that we’ve demonstrated so far. So, appreciate you joining us, and we’ll see you next quarter.
Operator: Thank you. This concludes today’s conference call. We thank you all for attending today’s presentation. You may now disconnect your lines and have a wonderful.
